James MacKay grew up in Scotland, and was encouraged by his father to pursue a career in business –but not the family business. Instead he earned a PhD in genetics and began a long stint with AstraZeneca, eventually jumping across the pond and all the way to San Diego. He continued with A companies like Ardea an now Arthrosi and Aristea, where he’s even done a deal with Arena.
In this episode of the HealthBiz podcast James talks about how he and his team at Aristea Therapeutics are applying their decades of experience to develop a drug they licensed from AstraZeneca. The first indication is PPP –no not purchasing power parity or the paycheck protection program– but palmoplantar pustulosis, a nasty illness with no good treatments today. We talk about why good drugs get left on the shelf at big pharma, and the future of the biotech industry and San Diego.